AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results
for Anti-Cancer Compound Perifosine at ASCO Meeting
Results showed an overall CBR of 52% which compares favorably withthe activity of mTOR inhibitors QUEBEC CITY, QC, June 04, 2007 /PRNewswire-FirstCall/ - AEterna
Zentaris Inc. , a global biopharmaceutical company focused onendocrine therapy and oncology, today announced that its partner,Keryx Biopharmaceuticals presented a poster outlining Phase 1 andPhase 2 results for perifosine, an oral...
AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2
Data for Ozarelix, in BPH at Annual AUA Meeting
Ozarelix improved LUTS symptoms and urine flow over 28-week period QUEBEC CITY, May 23, 2007 /PRNewswire-FirstCall/ - AEterna
Zentaris Inc. , a global biopharmaceutical company focused onendocrine therapy and oncology, today announced that its partnerSpectrum Pharmaceuticals presented an abstract outlining detailedPhase 2 results for AEterna
Zentaris' fourth-generation luteinizinghormone-r...
terna Zentaris Discloses First In Vitro Data for its PI3K
Inhibitors at the AACR Annual Meeting in Los Angeles
Second generationpyridopyrazine-urea derivative compound series show highlyselective PI3K-inhibition which could be valuable for cancertreatment QUBEC CITY, Canada, April16, 2007 terna
Zentaris Inc. (TSX: AEZ; Nasdaq:AEZS), a global, pure play biopharmaceutical company...
AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist
JMR-132 at the AACR Annual Meeting in Los Angeles
JMR-132 could provide a new therapeutic approach for the treatmentof early and metastatic breast cancer QUEBEC CITY, April 17, 2007 /PRNewswire-FirstCall/ - AEterna
Zentaris Inc. , a global, pure play biopharmaceutical companyfocused on endocrine therapy and oncology, today presented anabstract outlining in vivo data for its growth hormone-releasinghormone (GHRH) antagonist JMR-132 in brea...
AEterna Zentaris Discloses First In Vitro Data for its PI3K
Inhibitors at the AACR Annual Meeting in Los Angeles
Second generation pyridopyrazine-urea derivative compound seriesshow highly selective PI3K-inhibition which could be valuable forcancer treatment QUEBEC, April 16, 2007 /PRNewswire-FirstCall/ - AEterna
ZentarisInc. , a global, pure play biopharmaceutical company focused onendocrine therapy and oncology, today presented an abstractoutlining first in vitro data on its pyridopyrazine derivat...
More>>